A Randomized, Double-blind, Phase III Study of Gemcitabine +Carboplatin/Cisplatin Chemotherapy With or Without Sintilimab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (Orient-12)
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2018
Price : $35 *
At a glance
- Drugs Sintilimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-12
- Sponsors Innovent Biologics
- 29 Sep 2018 According to Innovent Biologics media release, the first patient has been dosed in this study.
- 29 Sep 2018 According to Innovent Biologics media release, Status changed from not yet recruiting to recruiting.
- 21 Aug 2018 New trial record